Streamlining Hematology Eligibility Verification for Complex Blood Disorders

The Criticality of Eligibility Verification in Hematology

Hematology practices manage patients requiring high-cost, often life-sustaining treatments such as factor concentrates for hemophilia, novel specialty drugs for sickle cell disease (e.g., voxelotor, crizanlizumab), and advanced therapies like CAR-T cells (e.g., Yescarta, Kymriah) or bone marrow transplants. Ensuring accurate **hematology eligibility verification** is paramount to prevent significant financial write-offs and ensure uninterrupted patient access to these critical therapies, where even a single missed verification can lead to substantial financial exposure.

Manual Eligibility Challenges for Complex Hematology Treatments

Traditional manual eligibility verification workflows, relying on staff logging into numerous payer portals or interpreting complex X12 271 responses, are prone to failure in hematology. These manual processes often lead to stale eligibility data, misinterpretation of benefit details for specific drug categories (e.g., prophylaxis vs. on-demand factor concentrates), and critically, missed identification of prior authorization requirements for high-cost biologics or imaging, directly contributing to claim denials and revenue leakage.

Klivira's Automated Approach to Hematology Eligibility Verification

• **Multi-channel Querying**: Submits X12 270 eligibility inquiries via clearinghouses and retrieves FHIR Coverage data from FHIR-conformant payers, including those adhering to CMS-0057-F Patient Access APIs.
• **Normalized Benefit Data**: Parses X12 271 responses and FHIR Coverage resources into a consistent, easily interpretable model, clarifying plan type, deductible status, copay/coinsurance, and in-network status specific to hematology service categories.
• **Proactive PA Gating**: Automatically identifies prior authorization requirements for planned hematology services (e.g., CAR-T, factor concentrates, specialty imaging) during eligibility checks, initiating the PA workflow without manual intervention.
• **Re-verification Logic**: Implements automated re-verification for high-cost, scheduled hematology procedures like bone marrow transplants or long-term infusion therapies, catching mid-period coverage changes before the date of service.
• **EMR Write-back**: Posts structured eligibility details directly into the EMR, either as a FHIR Coverage resource update or a clear, structured note for immediate clinician and administrative visibility.
• **Benefit Exhaustion Tracking**: Monitors and surfaces remaining benefits for specific categories, such as visit or cost caps, relevant for supportive care or ancillary services often accompanying hematology treatments.

Mitigating Hematology-Specific Denial Risks

Klivira's automation directly addresses common denial reasons in hematology. By catching stale eligibility data, it prevents denials for long-term treatments. Accurate parsing of 271 responses eliminates misinterpretations of complex benefit categories for novel agents. Crucially, automatically identifying PA requirements for procedures like factor concentrate prophylaxis or CAR-T cell therapy prevents 'PA not on file' denials, which are particularly costly in this specialty. The system also automates secondary coverage identification and coordination of benefits.

Seamless Integration with EMRs and Payer Channels

Klivira integrates with leading EMR systems to pull patient demographics and service orders, and write back verified eligibility data. For payers, Klivira leverages both standard X12 270/271 EDI transactions via clearinghouses and modern FHIR APIs (including those mandated by CMS-0057-F for patient access), ensuring comprehensive coverage across the payer landscape. This multi-channel approach guarantees that eligibility checks for hematology services, from routine labs to complex gene therapies, are performed efficiently and accurately.